In Brief This Week: Quest Diagnostics, Abbott, Biocept, Biocartis, Angle, Virax Biolabs
News items for the week of April 17, 2023.
Angle, BioView Partner to Develop Quantitative HER2 Assay Using Circulating Tumor Cells
The companies said recent developments in HER2-targeted therapies have created new commercial opportunities for a blood-based test.
The firm cited new study results confirming that an assay analyzing circulating tumor cells isolated by its Parsortix platform can discriminate malignant pelvic masses.
Angle Signs Distribution Deal for Parsortix Cell Sorting System in Czech Republic
The system was recently FDA cleared for the isolation of circulating metastatic breast cancer cells for liquid biopsy testing.
Angle Gets FDA Clearance for Breast Cancer Cell Isolation System
The system, called Parsortix, has been cleared for use in the isolation of circulating metastatic breast cancer cells for liquid biopsy testing.
Sep 30, 2021
Angle H1 Revenues Up 26 Percent
Jun 25, 2021
Angle to Raise £20M Through Stock Placement
Jul 31, 2019
Liquid Biopsy Firm Angle FY19 Revenues up 8 Percent
Jun 25, 2018